Detalhe da pesquisa
1.
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
J Am Acad Dermatol
; 90(1): 82-90, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37739267
2.
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
J Eur Acad Dermatol Venereol
; 38(5): 864-872, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38179809
3.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Br J Dermatol
; 189(5): 540-552, 2023 10 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37488811
4.
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
J Dermatolog Treat
; 35(1): 2342383, 2024 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38632977
5.
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.
J Dermatolog Treat
; 35(1): 2287401, 2024 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38073528
6.
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Rheumatol Ther
; 11(3): 617-632, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38498141
7.
Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States.
J Dermatolog Treat
; 34(1): 2200869, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37025014
8.
Dual pools of actin at presynaptic terminals.
J Neurophysiol
; 107(12): 3479-92, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22457456
9.
Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes.
Proc Natl Acad Sci U S A
; 106(31): 13058-63, 2009 Aug 04.
Artigo
Inglês
| MEDLINE | ID: mdl-19625617
10.
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
J Dermatolog Treat
; 33(7): 2991-2996, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35839335
11.
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Dermatol Ther (Heidelb)
; 12(2): 561-575, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35050485
12.
Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines.
Neuron
; 56(4): 640-56, 2007 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-18031682
13.
Presynaptic G-protein-coupled receptors dynamically modify vesicle fusion, synaptic cleft glutamate concentrations, and motor behavior.
J Neurosci
; 29(33): 10221-33, 2009 Aug 19.
Artigo
Inglês
| MEDLINE | ID: mdl-19692597
14.
Coordination of synaptic adhesion with dendritic spine remodeling by AF-6 and kalirin-7.
J Neurosci
; 28(24): 6079-91, 2008 Jun 11.
Artigo
Inglês
| MEDLINE | ID: mdl-18550750
15.
Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines.
Nat Neurosci
; 12(10): 1275-84, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19734897
16.
G protein betagamma-subunits activated by serotonin mediate presynaptic inhibition by regulating vesicle fusion properties.
Proc Natl Acad Sci U S A
; 103(11): 4281-6, 2006 Mar 14.
Artigo
Inglês
| MEDLINE | ID: mdl-16537522
17.
Location and function of vesicle clusters, active zones and Ca2+ channels in the lamprey presynaptic terminal.
J Physiol
; 569(Pt 1): 119-35, 2005 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16141275